Remix Therapeutics, Inc.

Venture-backed company · Stage unknown· Watertown, MAremixtx.com

As of Oct 30, 2026 · the latest observation of this company; each round carries its own date

2 rounds on record · Jan 3, 2024 latest roundAll 3

Rounds on record: 2
Latest round: Jan 3, 2024
Latest round size: $60.0M

Find My Intro Path

Form D industry: Biotechnology

People to knowView relationshipsAsk DFX about this

Financing history Capital evidence Investors Ownership and outcomes

As of Oct 30, 2026 · the latest observation of this company; each round carries its own date

Work here? Correct this profile

4 additional officers and directors

Every relationship, signal and contact on this record, with the source on each.

What matters now

8 investors
named
8 investors on record;
The investors already on the cap table shape who leads the next round.
Factfunding announcements, portfolio pages and Form DFor Investors, foundersInvestors →
7 directors
board
7 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
FactSEC Form D related personsFor Investors, acquirersPeople →

This network is drawn from the venture record DFX holds for Remix Therapeutics, Inc. (8 investors, 5 board members, 3 officers and people). The full map adds every documented relationship DFX holds across sources: lenders, advisers, owners and filings. It reads a separate relationship layer, so its counts can differ from these.

Open the full relationship map

Drawing the relationship network…

Who can introduce you

From your own network, read by Network Intelligence. Only you see this; nothing here is shared with anyone else.

Find My Intro Path

Sign in and add your LinkedIn connections to Network Intelligence to see who in your network can introduce you to Remix Therapeutics, Inc.. How it works

Facts

Year of incorporation: 2019sec.gov
Revenue range (Form D): Decline to Disclosesec.gov
Rounds on record: 2
Disclosed raised: $60.0Msum of rounds with a disclosed amount only
Named investors: 8

Monitor companies like this one

New Form D filings and rounds from companies in the same sector and state. Your mandate starts from life sciences, Massachusetts. Write it now; a free account saves it.

Set up a mandate Get the briefing by email Explore venture-backed companies in life sciences

Why this company matters

each line is a dated signal on record, linked to its evidence

Hiring: 5 open roles on its jobs board

Timeline

2 events

Jan 4, 2024
Remix Therapeutics, Inc. filed Form D: $13,740,355 sold of $90,000,000, Biotechnology
Form D filed Fact Form D
Jan 3, 2024
Remix Therapeutics announced Funding round of $60,000,000, led by Column Group
Round announced Fact Press release

Financing history

2 rounds

Jan 3, 2024
Funding round · $60.0M (disclosed)
The Column Group (lead) via Peter SvennilsonAtlas Venture (participant)Foresite Capital (participant)Alexandria Venture Investments (participant)Arch Venture Partners (participant)Casdin Capital, LLC (participant)Willett Advisors (participant)
Fact Press release · “Remix Therapeutics Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease”
Dec 22, 2023
Form D equity offering · $13.7M (form d sold) · 21 investors
Foresite Capital via Michael Rome
Fact Form D · “Remix Therapeutics, Inc.: Form D offering 021-501562 (1 filing(s) 2024-01-04 to 2024-01-04), $13,740,355 sold of $90,000,000, mixed, Biotechnology”

Capital evidence

where each capital claim on this record came from

Capital on filea primary record (a sworn filing, or the investor's or program's own page), or published records from two independent sources, show it raised outside capital.

First dated raise: Dec 22, 2023
Latest dated raise: Dec 22, 2023
Equity sold on record: $13.7M

Dec 22, 2023
form d sale (sold) · $13.7M (sold) · mixed
Tier A, primary record Form D · “Remix Therapeutics, Inc.: Form D offering 021-501562 (1 filing(s) 2024-01-04 to 2024-01-04), $13,740,355 sold of $90,000,000, mixed, Biotechnology”
undated
investor portfolio listing (listed) · Casdin Capital, LLC
Tier A, primary record investor portfolio page… · “WordPress venture item: Remix Therapeutics”
undated
investor portfolio listing (listed) · Atlas Venture
Tier A, primary record investor portfolio page atlasventure.com · “company page in sitemap: https://atlasventure.com/company/remix-therapeutics/”
undated
investor portfolio listing (listed) · Arch Venture Partners
Tier A, primary record investor portfolio page archventure.com · “WordPress company item: Remix Therapeutics”
undated
investor portfolio listing (listed) · The Column Group
Tier A, primary record investor portfolio page… · “WordPress portfolio item: Remix Therapeutics”
undated
investor portfolio listing (listed) · Foresite Capital
Tier A, primary record investor portfolio page… · “listed on https://www.foresitecapital.com/portfolio/: Remix Therapeutics (/portfolio/remix-therapeutics/)”
Sep 30, 2026
investor portfolio listing · Foresite Capital
Tier A, primary record Firm website · “listed on https://www.foresitecapital.com/portfolio/: Remix Therapeutics (/portfolio/remix-therapeutics/)”

Tier A is a primary record (a sworn filing, or the investor's or program's own page), B a published record, C a signal that is not confirmed capital. Amounts keep their kind: sold, offered, announced and debt principal are never added together.

Who would invest

8 investors on record, then the firms most like them

Already invested

8 investors on record

Atlas Venture Life Science Advisors, LLC board only, Kevin Bitterman (unknown) Inference sec.gov
Foresite Capital board only, Michael Rome (strongly supported) Inference sec.gov
Foresite Capital form d related, Michael Rome (strongly supported) Inference sec.gov

Strong comparable investors

10 firms

Firms that backed two or more of the companies this company's own investors also back.

GV
- Backed 4 companies this company's investors also back
- Co-invested 10 times with 4 of this company's investors
- Has joined rounds of $50M to $150M (32 on record)
- Invests in Life sciences
- 8 new companies dated in the last 12 months, latest Oct 21, 2026
Sofinnova Partners
- Backed 3 companies this company's investors also back
- Co-invested 9 times with 3 of this company's investors
- Has joined rounds of $50M to $150M (5 on record)
- Invests in Life sciences
- 3 new companies dated in the last 12 months, latest Jul 7, 2026
Research
- Backed 3 companies this company's investors also back
- Co-invested 8 times with 2 of this company's investors
- Has joined rounds of $50M to $150M (15 on record)
- Invests in Life sciences
- 2 new companies dated in the last 12 months, latest Jul 30, 2026

+7 more comparable investors

Broader fit

14 firms

Firms that co-invest repeatedly with this company's investors and dated a new company in the last 12 months.

OrbiMed
- Backed 1 company this company's investors also back
- Co-invested 22 times with 5 of this company's investors
- Has joined rounds of $50M to $150M (32 on record)
- Invests in Life sciences
- 3 new companies dated in the last 12 months, latest May 18, 2026
Decheng Capital LLC
- Backed 1 company this company's investors also back
- Co-invested 10 times with 2 of this company's investors
- Has joined rounds of $50M to $150M (9 on record)
- Invests in Life sciences
- 4 new companies dated in the last 12 months, latest Aug 14, 2026
LUX Capital Management, LLC
- Backed 1 company this company's investors also back
- Co-invested 8 times with 3 of this company's investors
- Has joined rounds of $50M to $150M (11 on record)
- Invests in Life sciences
- 5 new companies dated in the last 12 months, latest Sep 30, 2026

+11 more broader-fit firms

People

3 officers, 7 directors

Heather Wasserman Executive Officer sec.gov
Peter Smith Executive Officer/Director sec.gov
Robert Gagnon Executive Officer sec.gov
Jeff Goater Director Fact
Michael Rome Director Inference

Show 1 more officers and directors (6 in all)

Jeff Goater Director Inference

Ownership and outcomes

none on record

Outcome stated by investors

Listed on 1 firm portfolio page; none states an outcome (acquired, public, exited or active). DFX does not assume the company is active.

Evidence: 1 listingeach firm's own card, as read

1 more listing counted above; the firms are named with a plan.

No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.

Credit relationships

none on record

No lender position matched to this company.

Activity

1 on record

Hiring (1): 1 named on record, shown to members.

Evidence

23 observations

Every observation on this company

Entity type: Corporation Jan 4, 2024 Fact Form D
Form D industry group: Biotechnology Jan 4, 2024 Fact Form D
Amendment: false Jan 4, 2024 Fact Form D
Revenue range (Form D): Decline to Disclose Jan 4, 2024 Fact Form D
Incorporated: withinFiveYears Jan 4, 2024 Fact Form D
Jurisdiction: Delaware Jan 4, 2024 Fact Form D
Amount sold (Form D): $13.7M Jan 4, 2024 Fact Form D
Offering amount (Form D): $90.0M Jan 4, 2024 Fact Form D
Exemptions: 06b Jan 4, 2024 Fact Form D
First sale: 2023-12-22 Jan 4, 2024 Fact Form D
Investors (Form D): 21 Jan 4, 2024 Fact Form D
Minimum investment (Form D): 0 Jan 4, 2024 Fact Form D
Securities offered: Debt, option Jan 4, 2024 Fact Form D
Office address: Jan 4, 2024 Fact Form D
Listed on portfolio page: Oct 30, 2026 Fact
Listed on portfolio page: Oct 15, 2026 Fact
Listed on portfolio page: Sep 30, 2026 Fact
Listed on portfolio page: Sep 16, 2026 Fact
Listed on portfolio page: Sep 14, 2026 Fact
Round announced: Funding round $60,000,000 Jan 3, 2024 Fact Press release
Website status: ok Oct 3, 2026 Fact Company website
Site title: Oct 3, 2026 Fact Company website
Year of incorporation: 2019 Jan 4, 2024 Fact Form D

Company-intelligence sources (7)

sec form d 2024-01-04 sec_form_d · form-d-history-1
company ats 2026-10-22 company_ats · ats-jobs-1
sec edgar 2024-01-04 sec_edgar · sec-submissions-1
company site 2026-10-06 company_site · website-status-1
press release wire 2026-10-16 press_release_wire · vc_relationship.INVESTED_IN
dfx research 2026-10-02 dfx_research · vc_relationship.INVESTED_IN
dfx research 2026-10-02 dfx_research · vc_relationship.INVESTED_IN

Connected records

Investors

Atlas Venture Life Science Advisors, LLC (since 2024)
Foresite Capital (since 2024)

6 more on this record

Relationships across DFX

on 2 other DFX graphs · 2 capital paths

Across the graphs

Remix Therapeutics, Inc. is the same institution as 2 records in Private Equity and Independent Sponsors.

Private Equity1Independent Sponsors1

DFX found 2 relationships across 2 datasets

Which record it is in each graph, what it is called there, and how the two were matched.

Checking your plan…

Capital chain

Remix Therapeutics, Inc. sits on 2 traced paths of capital across the graphs.

Allocator to VC fund to manager to company

DFX traced 2 paths of capital through this record

Every record on each path, what it committed or lent, and as of when.

Derived from allocator disclosures, BDC schedules and SEC filings; confidence is the weakest hop.

Checking your plan…

Record history

2 dated events on the change ledger, latest event first

Form D filed
2024-01-04source on record
Round announced
2024-01-03source on record

The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.

What matters now

Who can introduce you

Facts

Why this company matters

Timeline

Financing history

Capital evidence

Who would invest

Already invested

Strong comparable investors

Broader fit

People

Ownership and outcomes

Credit relationships

Activity

Evidence

Connected records

Investors

▸Relationships across DFX

Record history

Who can introduce you

Relationship network

Relationships across DFX